Regenerative medicine is the next great step in modern healthcare, and will allow for the introduction of novel and innovative treatment options across important areas of medical need.
AMNICELL is the first company to use amniotic fluid derived stem cells for clinical use. Our cells are not from embryos or reprogrammed in order to become stem cells. Unlike other types of stem cells, amniotic fluid stem cells are uniquely suited for regenerative medicine for a number of reasons:
    - sourced from a natural human fluid discarded at birth, not from embryos
    - abundant and replicate rapidly
    - naturally ready to be used
    - retain their vitality after long-term cryo-storage
    - not associated with any increased risk for tumors
    - improve tolerance of transplants by suppressing immune reactions
    - shown to reduce inflammation and scarring

At AMNICELL, we will explore these characteristics to develop transformative treatments for serious medical conditions such as COVID-19 lung disease, non-healing wounds, and innovative therapies for hair and skin care. After 10 years of scientific research we have the technology to collect, store, preserve and package these cells for clinical use. Our initial focus is on the treatment of serious COVID-19 lung disease. We will also leverage our technology for novel advanced treatment of chronic non-healing wounds, which affect 6.5 million people in the US annually. A strong focus is also on novel hair and skin care treatments using the restorative power of amniotic fluid.